New TFO conjugates containing a carminomycinone-derived chromophore

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Biochemistry

Background:

• Triple helix forming oligonucleotides (TFOs) are DNA structures with therapeutic potential.
• Anthracycline compounds are known for their intercalating properties and anticancer activity.

Purpose of the Study:

• To investigate the physicochemical stability of triple helices formed by TFOs conjugated with anthracycline chromophores.
• To evaluate the efficacy of these conjugates in targeting pharmacologically relevant DNA sequences, including those in multidrug resistance (MDR) genes and HIV-1.

Main Methods:

• Synthesis of carminomycinone derivatives from daunomycin to create intercalating moieties.
• Conjugation of these moieties to TFOs designed to target specific DNA sequences.
• Physicochemical studies to assess triple helix stability and binding affinity using modified TFO sequences.

Main Results:

• Triple helix stability was significantly enhanced by replacing cytosine with 5-methylcytosine in TFOs targeting the MDR gene.
• The stability remained unchanged with specific sequence modifications at the anthraquinone intercalation site.
• Conjugates demonstrated significantly enhanced binding to the polypurine tract (PPT) of HIV-1 DNA compared to unconjugated TFOs.

Conclusions:

• Anthracycline-TFO conjugates represent a promising strategy for developing novel therapeutics.
• Sequence modifications in TFOs can be used to optimize triple helix stability and drug targeting.
• These conjugates show potential for targeting viral DNA, such as in HIV-1 infections.